The aggregation of proteins into amyloid fibrils and their deposition into plaques and
intracellular inclusions is the hallmark of amyloid disease. The accumulation and deposition …

Accumulating data from the clinical research support that the core Alzheimer's disease (AD)
cerebrospinal fluid (CSF) biomarkers amyloid‐β (Aβ42), total tau (T‐tau), and …

Despite recent advances in fluid biomarker research in Alzheimer's disease (AD), there are
no fluid biomarkers or imaging tracers with utility for diagnosis and/or theragnosis available …

The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ 42), total
Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau 181) have proven diagnostic …

Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

Cerebral amyloid angiopathy, which is defined by cerebrovascular deposition of amyloid β,
is a common age-related small vessel pathology associated with intracerebral haemorrhage …

Current technological advancements in clinical and research settings have permitted a more
intensive and comprehensive understanding of Alzheimer's disease (AD). This development …

Objective To determine whether following a Mediterranean-like diet (MeDi) relates to
cognitive functions and in vivo biomarkers for Alzheimer disease (AD), we analyzed cross …

Aggregation of amyloid-β (Aβ) into oligomers, fibrils, and plaques is central in the molecular
pathogenesis of Alzheimer's disease (AD), and is the main focus of AD drug development …

Alzheimer disease (AD) is biologically defined by the presence of β-amyloid-containing
plaques and tau-containing neurofibrillary tangles. AD is a genetic and sporadic …